Get started
Author

Abigail Xie

ORCID: 0000-0001-6771-1980
Observed ORCID: 0000-0001-6771-1980
OpenAlex ID: A5035337737
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
2021 · Sydney X. Lu, Emma De Neef, et al. · Cell · 287
PDF
Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
2016 · Kevin H. Lin, Peter S. Winter, et al. · Scientific Reports · 186
PDF
Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity
2019 · Kevin H. Lin, Abigail Xie, et al. · Cell Metabolism · 109
PDF
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer
2020 · Kevin H. Lin, Justine C. Rutter, et al. · Nature Genetics · 84
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia
2022 · Kevin H. Lin, Justine C. Rutter, et al. · Nature Cancer · 47
Citrate clearance is a major function of aconitase 2 in the canonical TCA cycle
2026 · Abigail Xie, Julia S. Brunner, et al. · Cell · 8
Aspartate availability drives differential engagement of the malate-aspartate shuttle
2026 · Julia S. Brunner, Anna E. Bridgeman, et al. · Molecular Cell · 8
p53 increases phospholipid headgroup scavenging in senescence
2026 · Jossie J. Yashinskie, Xianbing Zhu, et al. · Nature Cell Biology · 7
PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al. · Cancer Research · 4
PDF
Abstract 5742: Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
2023 · James D. Thomas, Sydney X. Lu, et al. · Cancer Research · 1
Supplementary Figure 2 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
PDF
Supplementary Table 1 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
Supplementary Figure 4 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
PDF
Supplementary Figure 5 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
PDF
Supplementary Figure 3 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
PDF
Supplementary Figure 7 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
PDF
Supplementary Figure 6 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
PDF
Supplementary Figure 1 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
PDF
Supplementary Table 3 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
Supplementary Table 2 from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
Data from PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
2025 · Katrina I. Paras, Julia S. Brunner, et al.
Works count: 21
Citation count: 740
H-index: 7
I10-index: 5
Year
Topic
Type